Portfolio Position: Teva Pharmaceuticals $TEVA
Teva Pharmaceuticals $TEVA has shed over 50% of its value following its $6.1B impairment charge and 75% dividend slash in its latest quarterly report.
Pros:
- The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN.
- Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals.
- The company is divesting its non-core organic revenue drivers, expected to bring in over $5B in 2017 and boost margins.
- Aggressive cost cutting, saving over $1.6B annually is expected to boost Net Income and Margins.
Risks:
- Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018.
- Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price.
Targets:
I initiate TEVA with a $30 PT for the next 12 months, throughout 2018.
For the full review: seekingalpha.com/art...va-complete-overview
Pros:
- The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN.
- Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals.
- The company is divesting its non-core organic revenue drivers, expected to bring in over $5B in 2017 and boost margins.
- Aggressive cost cutting, saving over $1.6B annually is expected to boost Net Income and Margins.
Risks:
- Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018.
- Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price.
Targets:
I initiate TEVA with a $30 PT for the next 12 months, throughout 2018.
For the full review: seekingalpha.com/art...va-complete-overview